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Dyslipidemia is a major risk factor for cardiovascular (CV) disease – the primary cause of death, worldwide. Although
reducing levels of low-density lipoprotein-cholesterol can significantly reduce CV risk, a high level of residual risk
persists, especially in people with obesity-related conditions, such as metabolic syndrome and type 2 diabetes
mellitus. Peroxisome proliferator-activated receptor alpha- (PPARα-) agonists (e.g. fibrates), play a central role in the
reduction of macro- and microvascular risk in these patients. However, the currently available fibrates are weak
(PPARα-agonists) with limited efficacy due to dose-related adverse effects. To address this problem, a new
generation of highly potent and selective PPARα-modulators (SPPARMα) is being developed that separate the
benefits of the PPARα-agonists from their unwanted side effects. Among these, aleglitazar (a dual PPARα/γ agonist)
and GFT505 (a dual PPAR α/δ agonist) have recently entered late-phase development. Although both compounds
are more potent PPARα-activators than fenofibrate in vitro, only aleglitezar is more effective in lowering triglycerides
and raising high-density lipoprotein-cholesterol (HDL-C) in humans. However, it is also associated with a potential
risk of adverse effects. More recently, a highly potent, specific PPARα-agonist (K-877) has emerged with SPPARMα
characteristics. Compared to fenofibrate, K-877 has more potent PPARα-activating efficacy in vitro, greater effects on
triglycerides- and HDL-C levels in humans, and a reduced risk of adverse effects. If successful, K-877 has the
potential to supersede the fibrates as the treatment of choice for patients with residual CV risk associated with
metabolic syndrome and type 2 diabetes.
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syndromeIntroduction
Dyslipidemia is a major risk factor for cardiovascular (CV)
disease – the leading cause of morbidity and mortality in
the developed world [1]. Lowering low-density lipoprotein-
cholesterol (LDL-C) levels using lifestyle change and
pharmacotherapy can significantly reduce CV risk in
people with and without cardiometabolic diseases, such as
metabolic syndrome (MetS) and type 2 diabetes mellitus
(T2D) [2-4]. However, the risk of macrovascular events in
those attaining the maximum levels of LDL-C reduction is
only reduced by around 30%, leaving substantial residualCorrespondence: jean-charles.fruchart@fondacoeur.com
Fondation coeur et arteres, 96, rue Nationale, 59000, Lille, France
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reproduction in any medium, provided the orrisk [2]. Moreover, the risk of microvascular events in
people with MetS or T2D can only be reduced by
approximately 50% using the current standard of care
(intensive treatment to reduce LDL-C, blood pressure
and blood glucose) [5]. Recent studies demonstrate that
low levels of high-density lipoprotein-cholesterol (HDL-
C) (<1.0 mmol/L; 40 mg/dL) and high levels of triglycer-
ides (TGs) (≥1.7 mmol/L; 150 mg/dL) are independent
risk factors for both macro- and microvascular diseases
[6-8]. Consequently, treatment guidelines highlight the
importance of targeting these risk factors in addition to
LDL-C [9]. This is particularly important for patients
with cardiometabolic diseases who often have athero-
genic dyslipidemia – a triad of lipid abnormalities thatThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ponderance of atherogenic small, dense LDL particles
[9-11]. In addition, patients with these lifestyle-related con-
ditions typically present with chronic inflammation and
other obesity-related risk factors, such as insulin resistance
and hyperglycemia. The ideal strategy for reducing CV risk
in patients with MetS or T2D should therefore encompass
many aspects of cardiometabolic control in addition to
lipid homeostasis [9,11].
Peroxisome proliferator-activated receptor alpha (PPARα)
agonists
Effects in vitro and in vivo
The PPARα-agonists (e.g. fibrates) play a central role in re-
ducing plasma concentrations of TG-rich lipoproteins, in-
creasing HDL-C levels and reducing vascular inflammation
in people with atherogenic dyslipidemia [10,12,13]. Fur-
thermore, PPARα-agonists can increase the stability of ath-
erosclerotic plaques, reduce the risk of atherothrombosis,
slow the progression of intimal hyperplasia following
surgery, and reduce hepatic fat accumulation leading to
non-alcoholic steatohepatitis/fatty liver disease (NASH/
NAFLD) [14]. The net effect of these actions is a significant
reduction in macrovascular events in people with, but not
without, atherogenic dyslipidemia [12,13,15-18], and sig-
nificant reductions in T2D-related microvascular events
[19-22]. For example, the Fenofibrate Intervention and
Event Lowering in Diabetes (FIELD) study demonstrated a
27% reduction in the risk of major CV events in patients
with atherogenic dyslipidemia (P<0.005) [23], a 14% reduc-
tion in albuminuria progression over 5 years (P<0.001)
[21], a 36% reduction in the risk of first amputation
(P=0.02) [19], and a 31% reduction in the need for first
laser treatment (P=0.0002) [20]. Although fibrates are the
only lipid-lowering drugs to demonstrate clinically signifi-
cant benefits for both macro- and microvascular disease in
people with T2D, they are weak PPARα-agonists whose ef-
ficacy is partly limited by dose-dependent side effects.
Commonly-reported adverse events (AEs) include eleva-
tions in markers for CV disease (e.g. homocysteine), renal
disease (e.g. creatinine) and liver dysfunction (e.g. alanine
aminotransferase [ALT] and γ-glutamyl transpeptidase)
[12,13,24]. There is therefore an unmet medical need for a
new generation of more potent PPARα-agonists with a
lower potential for AEs.
Mechanism of action
Three PPAR isoforms have been identified (PPARα,
γ and δ), each encoded by a separate gene [25]. PPARα is
abundant in highly active metabolic tissues including the
liver, kidney, heart, muscle, brown adipose and macro-
phages, whereas PPARγ is predominantly found in adipose
tissue, macrophages and large intestine. In contrast,
PPARδ (also called PPARβ) is ubiquitously expressed.PPARs are activated when endogenous ligands (e.g.
prostaglandins, leukotrienes, free fatty acids) or synthetic
PPAR agonists (e.g. glitazones, fibrates) bind to the lipid-
binding domain enabling heterodimerisation with a
ligand-activated retinoid X-receptor (RXR) [26-30]. This
process triggers a conformational change, leading to the
transrepression or transactivation of target genes. During
transrepression, the activated PPAR binds to cytokine-
activated transcription factors, such as nuclear factor
kappa B or activator protein-1 [31,32]. Under normal con-
ditions, these transcription factors induce the synthesis of
proteins involved in the inflammatory response. PPARs
can inhibit this process by blocking the interaction be-
tween activated transcription factors and the promoter re-
gion of the target gene, thereby preventing transcription
and reducing inflammation. During transactivation, the
activated PPAR binds to a specific sequence of nucleotides
(the PPAR receptor response element) upstream of the
target gene. A cofactor (either a coactivator or a corepres-
sor) renders the PPAR complex ‘transcriptionally active’
and gene transcription begins. A large number of genes
carry response elements for PPARs. Targets for PPARα in-
clude key genes involved in lipid metabolism, such as apo
A-I, A-II and A-V, LPL and SR-BI, whereas PPARγ targets
include genes involved in obesity and insulin resistance,
such as ADIPOQ and ADRP. Consequently, PPARα pri-
marily regulates lipid homeostasis [14], whereas PPARγ
largely regulates adipogenesis and glucose homeostasis
[33]. However, the precise receptor-mediated response de-
pends on the individual agonist and the tissue in which it
is expressed.
Compared to other nuclear receptors, PPARs have a
large lipid-binding pocket capable of encompassing a
range of endogenous ligands [34]. This provides a variety
of potential contact points that, when occupied, can trig-
ger different conformational changes. Since each PPAR
conformation is associated with a unique cofactor recruit-
ment pattern, the same PPAR subtype has the potential to
induce a wide range of biological effects depending on its
agonist (Figure 1). The number of possible effects is fur-
ther increased by the fact that PPAR-activation requires
both a specific ligand and an activated RXR complex, the
concentration and affinity of which can vary between tis-
sues, organs, and individuals. It is therefore possible for a
ligand to act as a full agonist in a tissue where sufficient
concentrations of a specific coactivator are present, and as
a partial agonist in another tissue with higher concentra-
tions of the same coactivator. For example, gemfibrozil
and fenofibrate (both PPARα-agonists) have a similar im-
pact on levels of HDL-C, TG and small dense LDL but,
whereas fenofibrate (a full PPARα-agonist) has additional
benefits on apolipoprotein A-I (apo A-I) and fibrinogen
levels [35], gemfibrozil (a partial PPARα-agonist) has little
or no effect [36]. Moreover, whereas most fibrates
Figure 1 PPAR-agonists have the potential to trigger different
biological responses via the same receptor [34].
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agonist, activating all three PPAR subtypes (α, γ and δ) at
comparable doses [37]. Although this effect can be
exploited to increase the number of biological benefits, it
can also be associated with an increased risk of unwanted
side effects. Consequently, the development of ideal
PPAR-agonists involves a series of in vitro and in vivo as-
says to identify the most potent molecules that differen-
tially induce receptor-mediated beneficial effects in
specific tissues whilst avoiding unwanted side effects [34].Figure 2 SPPARMα characteristics. ALT alanine aminotransferase; Apo ap
transpeptidase; HDL high-density lipoprotein; NASH/NASFL non-alcoholic sThis is the pharmacological basis for the selective PPARα
modulators (SPPARMs) (Figure 2).The next generation of selective PPARα modulators
The concept of SPPARMs (and other selective nuclear re-
ceptor modulators) was initially based on the paradigm of
tamoxifen, a pioneering selective estrogen receptor modu-
lator that exhibits anti-estrogenic activity in the mammary
gland and partial pro-estrogenic activity in bone and uterus
[38]. The observed increase in the incidence of uterine can-
cer with prolonged tamoxifen use led to the development
of raloxifene, a second-generation estrogen receptor modu-
lator with highly selective, tissue-specific activity that
avoids uterotrophic effects. Since then, selective modula-
tors have been identified for most classes of ligand-
modulated nuclear receptor [39]. For example, a number
of PPARγ-agonists with SPPARM properties (e.g. INT131
and MK0533) have been developed for the treatment of
T2D [40,41]. Preclinical studies show that these molecules
have comparable or more potent antidiabetic benefits to
the gold-standard treatment, pioglitazone, with fewer AEs
[41]. More recently, the SPPARM concept has been ex-
tended to other PPAR subtypes, including PPARα. If suc-
cessful, these molecules have the potential to become
superior therapeutics for the treatment of CV risk associ-
ated with MetS and T2D.olipoprotein; FGF-21 fibroblast growth factor 21; γGT γ-glutamyl
teatohepatitis/fatty liver disease; NR nuclear receptor; TG triglyceride.
Figure 3 Chemical structures of PPARα agonists.
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Whereas PPARα-agonists can improve lipid control and
PPARγ-agonists can improve glucose homeostasis, dual
PPARα/γ-or α/δ agonists can potentially be used to treat a
range of cardiometabolic imbalances at the same time.
Moreover, these molecules can be designed to offset each
other’s side effects [26,42]. For example, weight increases
due to the adipogenic effects of PPARγ-agonists can po-
tentially be negated by PPARα-mediated increases in lipid
catabolism. Although many dual PPAR-agonists have
undergone clinical trials, none have progressed past Phase
III due to unresolved safety concerns [42]. Muraglitazar,
tesaglitazar, ragaglitazar, TAK559 and KRP292, for ex-
ample, were discontinued due to an increased risk of CV
events, renal dysfunction, weight gain and edema. How-
ever, two dual agonists with possible SPPARM propertiesTable 1 Effects of PPARα-agonists on PPAR transcriptional ac
Compound Aleglitazar [26] G
PPARα EC50 (nM) 5
PPARγ EC50 (nM) 9
PPARδ EC50 (nM) 376 1
EC50 effective concentration inducing 50% response; NA not available.(aleglitazar and GFT505) have recently entered late-phase
development.
Aleglitazar (Figure 3) is a dual PPARα/γ-agonist devel-
oped by Roche Holding for the treatment of residual
CV risk in people with T2D [26,43,44]. Compared to
pioglitazone, it is a more potent PPARγ-agonist with greater
effects on glucose homeostasis and a reduced risk of
AEs [26]. In addition to its PPARγ agonist properties,
aleglitazar is a more potent PPARα-agonist than fenofibrate,
both in vitro (Table 1) [26] and in vivo (Table 2) [44]. For
example, a Phase II study in 332 people with T2D showed
that 16 weeks treatment with aleglitazar 150 μg once daily
(QD) was associated with significant placebo-adjusted
changes in both TG (−43.4%) and HDL-C (+20.7%)
(Table 2) [44]. In comparison, 16 weeks treatment with
fenofibrate 200mg QD in the FIELD study reduced TG
levels by 28.6% vs. placebo and increased HDL-C by 5.1%
(Table 2) [12]. Although aleglitazar has greater PPARα-
mediated effects on the lipid profile than fenofibrate, it is
associated with several potential safety concerns, including
weight gain, peripheral edema and increased creatinine
kinase levels with corresponding decreases in estimated
glomerular filtration rate [43-46]. Since it is unable to
completely separate the beneficial effects of the PPARα-
agonists from their unwanted AEs, aleglitazar is unlikely
to be classified as a true SPPARMα.
Another dual agonist with SPPARM characteristics is
GFT505 (Figure 3) [47,48]. Developed by GenFit, GFT505
is a dual PPARα/δ-agonist with preferential activity on
PPARα (Table 1) [48]. Phase II studies in people with com-
bined dyslipidemia and abdominal obesity (N = 97) or pre-
diabetes (N = 47) showed that 28 days treatment with
GFT505 80mg QD was associated with significant reduc-
tions in ALTand γ-glutamyl transpeptidase levels (Table 3)
[48], suggesting potential benefits for GFT505 in patients
with NASH/NAFLD. This is particularly important be-
cause, although the obesity-related incidence of fatty liver
disease continues to rise, no effective treatments are cur-
rently available [49]. However, although GFT505 was asso-
ciated with significant placebo-adjusted changes in the
levels of TGs (−16.7% to −24.8%) and HDL-C (+7.8%
to +9.3%) [48], the magnitude of the effects was similar to
those obtained in clinical studies with fenofibrate (Table 2)
[12]. GFT505 is, therefore, unlikely to be classified as a
true SPPARMα due to its lack of superior lipid-modifying
efficacy vs. fenofibrate.tivity
FT505 [48] K-877 [52] Fenofibrate [26,52]
10 to 20 1 14,000 [52]; 22,400 [26]
NA 2,300 ~100,000
00 to 150 1,000 not activated
Table 2 Effects of PPARα-agonists on triglycerides (TG) and high-density lipoprotein-cholesterol (HDL-C) levels
Compound Aleglitazar GFT505 K-877 Fenofibrate
Study SYNCHRONY [43,44] S1 [48] S2 [48] K-877 P2 [50] FIELD [12] K-877 [50]
Dosage 150 μg QD 80 mg QD 80 mg QD 100 μg BID 200 mg QD 100 mg QD
Time point (weeks) 16 4 4 12 16 12
TG
Baseline (mg/dL) 157.7* 283.5 194.9 290.9 172.8 325.2
Change vs. baseline NA −51.4 −62.9 NA NA NA
(mg/dL)
% change vs. baseline −29.7** NA NA −41.4 NA −30.7
% change vs. placebo −43.4** −16.7** −24.8** −69.9 −28.6 −59.2
HDL-C
Baseline (mg/dL) 46.8 34.8 46.4 40.9 42.5 40.1
Change vs. baseline NA 2.7 3.1 NA NA NA
(mg/dL)
% change vs. baseline 25.1** NA NA 16.9 NA 13.0
% change vs. placebo 20.7** 7.8** 9.3** 18.2 5.1 14.3
BID twice daily; NA, not available; QD once daily;
Where necessary, values were multiplied by 88.6 for TG and by 38.67 for HDL-C to convert from mmol/L to mg/dL.
Values are expressed as means unless otherwise stated.
*Median.
**Least squares means.
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K-877 (Kowa Co. Ltd.) is a highly potent and selective
PPARα-agonist with SPPARM properties (Figure 2) [50-52].
It is currently undergoing Phase I trials in Europe and the
USA and Phase III trials in Japan for the treatment of
atherogenic dyslipidemia. K-877 contains an acidic region
similar to that found in other PPARα-agonists but, to en-
hance PPARα activity and selectivity, unique benzoxazole
and phenoxyalkyl side-chains have been added (Figure 3)
[53]. Cell-based transactivation assays using hPPAR-GAL-4
chimeric receptors confirmed that, compared to fenofibrate,
K-877 is a more potent PPARα-agonist, with a high degree
of PPAR subtype-selectivity (Table 1) [52].
Pre-clinical studies in animal models for obesity demon-
strated that low doses of K-877 (0.3-3.0mg/kg) had a
greater TG-lowering efficacy than 1,000-fold higher dosesTable 3 Safety parameters
Compound Aleglitazar GFT5
Study SYNCHRONY [43,44] S1 [48]
Dosage 150 μg QD 80mg QD
Time point (weeks) 16 4
ALT (UI/L) NA −7.1
γGT (UI/L) NA −11.0
Serum creatinine (mg/dL) NA 0.038*
Homocysteine (nmol/mL) NA 1.71
ALT alanine aminotransferase; BID twice-daily; γGT γ-glutamyl transpeptidase; NA n
Data are expressed as mean changes from baseline.
*To convert from μmol/L to mg/dL, values were divided by 88.4.(300mg/kg) of fenofibrate, an effect that was accompanied
by higher levels of plasma FGF-21 [52]. Furthermore, K-
877 0.01-0.1 mg/kg significantly reduced atherosclerotic
lesion area in LDL receptor-null mice fed a Western diet,
and significantly reduced the expression of TNF-α and
MCP-1 genes. Although there were slight reductions in all
three of these parameters with fenofibrate 100mg/kg, the
benefit was not significant.
More recently, a Phase II 12-week dose-finding study
(N = 224) showed that K-877 100 μg twice daily (BID) was
well tolerated and had a greater lipid modifying efficacy
than fenofibrate 100mg QD in patients with atherogenic
dyslipidemia (13% with T2D) [50]. The incidences of AEs
(47.4% with K-877, 47.2% with placebo and 56.8% with
fenofibrate) and adverse drug reactions (5.3% with K-877,
8.3% with placebo and 10.8% with fenofibrate) were similar05 K-877 Fenofibrate
S2 [48] K-877 P2 [50] FIELD [12] K-877 [50]
80mg QD 100 μg BID 200mg QD 100mg QD
4 12 16 12
−2.1 −7.6 NA −4.2
−6.0 −24.6 NA 0.0
0.057* 0.013 NA 0.086
−0.8 0.16 NA 2.21
ot available; QD once daily.
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No serious AEs were reported for K-877. As expected,
fenofibrate was associated with significant increases vs.
baseline in serum creatinine and homocysteine levels and
little or no effect on ALT or γ-glutamyl transpeptidase
levels (Table 3). In contrast, K-877 100 μg BID had little or
no effect on CV or renal markers, and hepatic markers
were improved. Together, these results suggest that K-877
has a better safety and tolerability profile than fenofibrate
and might be useful for people with NASH/NAFLD.
As suggested by pre-clinical studies, the Phase II study
demonstrated greater changes from baseline in fasting
plasma TG and HDL-C levels with K-877 100 μg BID than
with fenofibrate in people with atherogenic dyslipidemia
(Table 2). Compared to placebo, significant changes in
TG, HDL-C, non-HDL-C and very low-density lipoprotein
were observed for K-877. Although not directly compared,
all changes were more pronounced with K-877 than with
fenofibrate. In addition, K-877 was associated with greater
beneficial changes in the size of atherogenic lipoproteins
than fenofibrate [50], suggesting that K-877 has the poten-
tial to improve lipoprotein quality as well as quantity.
Results from a ‘Cookie test’ [54] subanalysis (N = 143)
showed that 12 weeks treatment with K-877 had a signifi-
cantly greater potential than fenofibrate to improve post-
prandial hyperlipidemia, a major risk factor for CV disease
in people with MetS or T2D [51]. For example, K-877
suppressed the postprandial increase in TG, apo B-48 and
remnant-like particle cholesterol, a major risk factor for is-
chemic heart disease [55]. Although no clear between-
group differences in glucose or insulin levels were ob-
served in the substudy, results from the Phase II trial
showed that K-877 was associated with significant in-
creases in plasma levels of FGF-21. Similarly, K-877 was
associated with increased levels of FGF21 gene expression
in the livers of LDL receptor-null mice and increased
levels of plasma FGF-21 in ZF rats [52]. These observa-
tions are important because FGF21 expression in white
adipose tissue increases in response to feeding and is
generally associated with weight loss, antidiabetic and
hypolipidemic effects in animal models of T2D and obes-
ity [56,57]. Further studies are required to fully understand
the implications of these results and to examine the effects
of K-877 on vascular inflammation in humans.Conclusions
Fibrates play a central role in the reduction of macro- and
microvascular risk associated with MetS and T2D
[12,13,20-23]. However, they are weak PPARα agonists with
limited efficacy due to dose-related AEs. To address this
problem, a new generation of tissue-specific PPARα ago-
nists— the SPPARMαs— is being developed that separates
the receptor-mediated beneficial effects of the PPARαagonists from their unwanted side effects. Although a num-
ber of dual PPARα/γ and α/δ-agonists have been developed
with SPPARMα characteristics, most are associated with
unresolved safety issues [26,42-44] or fail to provide a su-
perior efficacy vs. standard treatment [47,48].
Recently, a highly specific PPARα-agonist (K-877) has
emerged with SPPARM properties. Although K-877 has
not been compared with fenofibrate in head-to-head
studies, it is approximately 10,000-fold more potent than
fenofibrate in vitro [52], has a greater lipid-modifying effi-
cacy at considerably lower doses both in animal models
for obesity/T2D and in humans, and is associated with an
improved safety/tolerability profile [50-52]. In addition,
K-877 100 μg BID is associated with beneficial changes in
markers for liver disease. This suggests that, in addition to
improving lipid parameters in people with cardiometabolic
diseases, K-877 might also be useful for the prevention
of NASH/NAFLD. Further studies are required to
characterize the effects of K-877 on the recruitment of co-
factors and gene expression to clarify the precise molecu-
lar mechanism, and to investigate the long-term safety
and clinical efficacy of K-877 in people with atherogenic
dyslipidemia. However, results to date suggest that K-877
is the first true member of the SPPARMα family. If suc-
cessful, this next generation of PPARα-agonists has the
potential to supersede fibrates as the treatment of choice
in patients with atherogenic dyslipidemia and could have a
major impact on the management of residual macro- and
microvascular risk associated with MetS and T2D.
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